WebSystemic delivery, local activity Bonum Therapeutics is focused on a proven technology that utilizes allosteric regulation to create targeted, highly active, and less toxic medicines. WebNov 15, 2024 · Bonum Therapeutics has raised a total of $93M in funding over 1 round. This was a Series A round raised on Nov 15, 2024. Bonum Therapeutics is funded by 6 investors. Roche Venture Fund and Digitalis Ventures are the most recent investors.
www.businesswire.com
WebSep 7, 2024 · Bonum continuing Good work after $250M cash acquisition deal with Roche. Sep. 7, 2024. Privately held Good Therapeutics Inc. entered a merger agreement in which Roche Holding AG will gain rights to a conditionally active PD-1-regulated IL-2 program, as well as exclusive rights to the platform technology for development of PD-1-regulated IL-2 ... WebSep 8, 2024 · Sequel company Bonum emerges in wake of Roche’s Good Tx acquisition ... RHHBY) is paying $250 million upfront for rights to the PD-1-regulated IL-2 program from Good Therapeutics Inc., and an exclusive right to the biotech’s platform technology for the development of additional PD-1-regulated IL-2 receptor agonists. Good Tx is also eligible ... chicken and slicks diner drive ins and dives
Privacy Policy – Bonum Tx
WebOur physicians, practicing at Bonum Health, are specifically trained to assess and currently provide specialized viral treatment of patients presenting with the myriad of symptoms … WebNov 29, 2024 · Bonum Therapeutics, Inc. - Most recent fund raising on November 29, 2024 raised $45,041,421 in Equity WebDec 22, 2024 · Bonum Therapeutics General Information. Description. Developer of protein-based drugs intended to create drugs with regulated, context-dependent activity. … chicken and skin chips